GoKawiilFDA clears WashU-derived PrecivityAD2 blood test for Alzheimer's diagnosis
The FDA has cleared PrecivityAD2, a blood test built on technology from Washington University School of Medicine, to help identify amyloid plaques linked to Alzheimer's disease. Developed by WashU spinoff C2N Diagnostics, the test uses high-resolution mass spectrometry to quantify biomarkers with over 90% accuracy, offering a less invasive option than spinal taps or brain imaging.
GoKawiil's interpretation of the reporting above, not reported fact.
Because newly available Alzheimer's drugs work best when started early, a simple blood test could dramatically expand access to timely diagnosis compared to costly, invasive procedures like lumbar punctures or PET scans. This clearance also validates mass spectrometry as a viable, more precise alternative to immunoassay-based blood tests already on the market.
- FDA clearance greenlights PrecivityAD2 for clinical use in evaluating Alzheimer's disease.
- The test relies on mass spectrometry, differing from other cleared immunoassay-based blood tests.
- Earlier diagnosis matters more now that disease-slowing treatments are available and time-sensitive.
The End of Alzheimer's by Dale Bredesen — If this FDA clearance has you thinking about brain health and early detection, this bestselling book from neurologist Dale Bredesen digs into the science of Alzheimer's and lifestyle factors tied to cognitive decline. It's an accessible companion for readers wanting to understand what a biomarker result might mean and what steps come next.
See The End of Alzheimer's by Dale Bredesen on Amazon → Affiliate link — we may earn a commission on purchases, at no extra cost to you. Product picked by AI based on this article; it is not a tested recommendation.Source: medicine.washu.edu — Shawn Ballard, 2026-08-24
Published there as: “FDA clears blood test to aid evaluation for Alzheimer's disease”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.